IP Library Granted Patent US 10,202,626
Granted Patent B2
US 10,202,626 · App. 15/078,874 · Granted Feb 12, 2019

Compositions and methods for producing benzylisoquinoline alkaloids

Inventors: Christina D. Smolke (Menlo Park, CA); Kristy M. Hawkins (Oakland, CA)
Assignee: California Institute of Technology
C12P17/12C12N9/0022C12N9/0059C12N9/1007C12N9/1096C12N9/88C12N15/81C12P7/24C12P13/001C12P17/182
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,202,626
App. No.
15/078,874
Granted
Feb 12, 2019
Kind
B2
Abstract

The present invention relates to host cells that produce compounds that are characterized as benzylisoquinolines, as well as select precursors and intermediates thereof. The host cells comprise one, two or more heterologous coding sequences wherein each of the heterologous coding sequences encodes an enzyme involved in the metabolic pathway of a benzylisoquinoline, or its precursors or intermediates from a starting compound. The invention also relates to methods of producing the benzylisoquinoline, as well as select precursors and intermediates thereof by culturing the host cells under culture conditions that promote expression of the enzymes that produce the benzylisoquinoline or precursors or intermediates thereof.

Claims (40)

1. A method for the production of a benzylisoquinoline alkaloid product, the method comprising:

culturing an engineered non-plant cell under conditions suitable for protein production, the engineered non-plant cell comprising two heterologous coding sequences, wherein the two heterologous coding sequences encode a first and second enzyme, respectively, that are involved in a metabolic pathway that converts tyrosine into the benzylisoquinoline alkaloid product, wherein the first and second enzymes are operably connected along the metabolic pathway,

wherein the benzylisoquinoline alkaloid product is selected from the group consisting of a norcoclaurine, coclaurine, N-methylcoclaurine, 3′-hydroxy-N-methylcoclaurine, reticuline, 6-O-methyl-norlaudanosoline, 6-O-methyl-laudanosoline, laudanine, scoulerine, tetrahydrocolumbamine, canadine, salutaridine, salutaridinol, salutaridinol-7-O-acetate, and thebaine,

wherein the first enzyme involved in the metabolic pathway that produces the benzylisoquinoline alkaloid product catalyzes at least one reaction that is selected from the group consisting of: Tyrosine to L-DOPA; L-DOPA to Dopamine; 4-hydroxyphenylacetaldehyde and Dopamine to Norcoclaurine; Tyrosine to 4-hydroxyphenylpyruvate; and 4-hydroxyphenylpyruvate to 4-hydroxyphenylacetaldehyde,

wherein the second enzyme involved in the metabolite pathway that produces the benzylisoquinoline alkaloid product catalyzes at least one reaction that is selected from the group consisting of: Norcoclaurine to Coclaurine; Coclaurine to N-Methylcoclaurine; N-Methylcoclaurine to 3′-hydroxy-N-methylcoclaurine; 3′-hydroxy-N-methylcoclaurine to Reticuline; Norlaudanosoline to 6-O-methyl-norlaudanosoline; 6-O-methyl-norlaudanosoline to 6-O-methyl-laudanosoline; 6-O-methyl-laudanosoline to Reticuline; Reticuline to Laudanine; Reticuline to Scoulerine; Scoulerine to Tetrahydrocolumbamine; Tetrahydrocolumbamine to Canadine; Reticuline to Salutaridine; Salutaridine to Salutaridinol; Salutaridinol to Salutaridinol-7-O-acetate; and Salutaridinol-7-O-acetate to Thebaine; and

wherein an enzyme of the first and second enzymes catalyzes a reaction that produces the benzylisoquinoline alkaloid product.

2. The method of claim 1 , wherein the engineered non-plant cell is selected from the group consisting of microbial cells, insect cells, mammalian cells, bacterial cells, and yeast cells.

3. The method of claim 1 , wherein the engineered non-plant cell is cultured under in vitro conditions.

4. The method of claim 1 , wherein the engineered non-plant cell is cultured under in vivo conditions.

5. The method of claim 1 , wherein the engineered non-plant cell is cultured with a compound selected from the group consisting of tyrosine, tyramine, dopamine, 4-hydroxyphenylacetaldehyde, 4-hydroxyphenylpyruvate, norcoclaurine, coclaurine, N-methylcoclaurine, 3′-hydroxy-N-methylcoclaurine, reticuline, scoulerine, tetrahydrocolumbamine, laudanosoline, and norlaudanosoline.

6. The method of claim 1 , further comprising:

recovering the benzylisoquinoline alkaloid product from the cell culture.

7. The method of claim 6 , wherein the engineered non-plant cell is cultured with tyrosine, and wherein the recovered benzylisoquinoline alkaloid product is norcoclaurine.

8. The method of claim 6 , wherein the engineered non-plant cell is cultured with tyrosine, and whecrein the recovered benzylisoquinoline alkaloid product is reticuline.

9. The method of claim 1 , wherein recovering the benzylisoquinoline alkaloid product from the cell culture comprises separating the benzylisoquinoline alkaloid product from cellular material to provide a product stream having the benzylisoquinoline alkaloid product.

10. The method of claim 1 , wherein the benzylisoquinoline alkaloid product is selected from the group consisting of norcoclaurine, coclaurine, N-methylcoclaurine, 3′-hydroxy-N-methylcoclaurine, reticuline, 6-O-methyl-laudanosoline, laudanine, scoulerine, tetrahydrocolumbamine, canadine, salutaridine, salutaridinol, salutaridinol-7-O-acetate, and thebaine.

11. A method for the production of a benzylisoquinoline alkaloid product, the method comprising:

culturing an engineered non-plant cell under conditions suitable for protein production, the engineered non-plant cell comprising two heterologous coding sequences, wherein the two heterologous coding sequences encode a first and second enzyme, respectively, that are involved in a metabolic pathway that converts tyrosine into the benzylisoquinoline alkaloid product, wherein the first and second enzymes are operably connected along the metabolic pathway,

wherein the benzylisoquinoline alkaloid product is a protoberberine product,

wherein the first enzyme involved in the metabolic pathway that produces the benzylisoquinoline alkaloid product catalyzes at least one reaction that is selected from the group consisting of: Tyrosine to L-DOPA; L-DOPA to Dopamine; 4-hydroxyphenylacetaldehyde and Dopamine to Norcoclaurine; Tyrosine to 4-hydroxyphenylpyruvate; and 4-hydroxyphenylpyruvate to 4-hydroxyphenylacetaldehyde,

wherein the second enzyme involved in the metabolic pathway that produces the benylisoquinoline alkaloid product catalyzes at least one reaction that is selected from the group consistin, of: Norcoclaurine to Coclaurine; Coclaurine to N-Methylcoclaurine; N-Methylcoclaurine to 3′-hydroxy-N-mehylcoclaurine; 3′-hydroxy-N-methylcoclaurine to Reticuline; Norlaudanosoline to 6-O-methyl-norlaudanosoline; 6-O-methyl-norlaudanosoline to 6-O-methyl-laudanosoline; 6-O-methyl-laudanosoline to Reticuline; Reticuline to Scoulerine; Scoulerine to Tetrahydrocolumbamine; and Tetrahydrocolumbamine to Canadine, and

wherein an enzyme of the first and second enzymes catalyzes a reaction that produces the protoberberine product.

12. The method of claim 11 , wherein the protoberberine product is selected from the group consisting of scoulerine, tetrahydrocolumbamine, and canadine.

13. A method for the production of a benzylisoquinoline alkaloid product, the method comprising:

culturing an engineered non-plant cell under conditions suitable for protein production, the engineered non-plant cell comprising two heterologous coding sequences, wherein the two heterologous coding sequences encode a first and second enzyme, respectively, that are involved in a metabolic pathway that converts tyrosine into the benzylisoquinoline alkaloid product, wherein the first and second enzymes are operably connected along the metabolic pathway,

wherein the benzylisoquinoline alkaloid product is a promorphinan product,

wherein the first enzyme involved in the metabolic pathway that produces the benzylisoquinoline alkaloid product catalyzes at least one reaction that is selected from the group consisting of: Tyrosine to L-DOPA; L-DOPA to Dopamine; 4-hydroxyphenylacetaldehyde and Dopamine to Norcoclaurine; Tyrosine to 4-hydroxyphenylpyruvate; and 4-hydroxyphenylpyruvate to 4-hydroxyphenylacetaldehyde,

wherein the second enzyme involved in the metabolic pathway that produces the benzylisoquinoline alkaloid product catalyzes at least one reaction that is selected from the group consisting of: Norcoclaurine to Coclaurine; Coclaurine to N-Methylcoclaurine; N-Methylcoclaurine to 3′-hydroxy-N-methylcoclaurine; 3′-hydroxy-N-methylcoclaurine to Reticuline; Norlaudanosoline to 6-O-methyl-norlaudanosoline; 6-O-methyl-norlaudanosoline to 6-O-methyl-laudanosoline; 6-O-methyl-laudanosoline to Reticuline; Reticuline to Salutaridine; Salutaridine to Salutaridinol; and Salutaridinol to Salutaridinol-7-O-acetate, and

wherein an enzyme of the first and second enzymes catalyzes a reaction that produces the promorphinan product.

14. The method of claim 13 , wherein the promorphinan product is selected from the group consisting of salutaridine, salutaridinol, and salutaridinol-7-O-acetate.

15. A method for the production of a benzylisoquinoline alkaloid product, the method comprising:

culturing an engineered non-plant cell under conditions suitable for protein production, the engineered non-plant cell comprising two hetcrologous coding sequences, wherein the two heterologous coding sequences encode a first and second enzyme, respectively, that are involved in a metabolic pathway that converts tyrosine into the benzylisoquinoline alkaloid product, wherein the first and second enzymes are operably connected along the metabolic pathway,

wherein the benzylisoquinoline alkaloid product is a 1-benzylisoquinoline alkaloid product,

wherein the first enzyme involved in the metabolic pathway that produces the benzylisoquinoline alkaloid product catalyzes at least one reaction that is selected from the group consisting of: Tyrosine to L-DOPA: L-DOPA to Dopamine; 4-hydroxyphenylacetaldehyde and Dopamine to Norcoclaurine; Tyrosine to 4-hydroxyphenylpyruvate; and 4-hydroxyphenylpyruvate to 4-hydroxyphenylacetaldehyde,

wherein the second enzyme involved in the metabolic pathway that produces the benzylisoquinoline alkaloid product catalyzes at least one reaction that is selected from the group consisting of: Norcoclaurine to Coclaurine; Coclaurine to N-Methylcoclaurine; N-Methylcoclaurine to 3′-hydroxy-N-methylcoclaurine; 3′-hydroxy-N-methylcoclaurine to Reticuline; Norlaudanosoline to 6-O-methyl-norlaudanosoline; 6-O-methyl-norlaudanosoline to 6-O-methyl-laudanosoline; and 6-O-methyl-laudanosoline to Reticuline, and

wherein an enzyme of the first and second enzymes catalyzes a reaction that produces the 1-benzylisoquinoline alkaloid product.

16. The method of claim 15 , wherein the 1-benzylisoquinoline alkaloid product is selected from the group consisting of norcoclaurine, coclaurine, N-methylcoclaurine, 3′-hydroxy-N-methylcoclaurine, 6-O-methyl-norlaudanosoline, 6-O-methyl-laudanosoline, and reticuline.

17. The method of claim 1 , further comprising incorporating the benzylisoquinoline alkaloid product into a compound having analgesic properties.

18. The method of claim 1 , further comprising incorporating the benzylisoquinoline alkaloid product into a compound having antimalarial properties.

19. The method of claim 1 , further comprising incorporating the benzylisoquinoline alkaloid product into a compound having cancer therapeutic properties.

Assignments (3)
SECURITY INTEREST Recorded Aug 29, 2025
From: ANTHEIA, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 072750/0812 →
CONFIRMATORY LICENSE Recorded May 22, 2016
From: CALIFORNIA INSTITUTE OF TECHOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 038672/0169 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2016
From: SMOLKE, CHRISTINA D; HAWKINS, KRISTY
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 038255/0581 →
Continuity (5)
Continuation 14614484 · Feb 5, 2015
Division 11875814 · Oct 19, 2007
Provisional Application 60859149 · Nov 15, 2006
Provisional Application 60852954 · Oct 19, 2006
Related Publication 20160304923A1 · Oct 20, 2016